Study
Clinical Study: 12, Number of patients: 365
70% more patients taking BioCardine®Omega-3 together with the medicines achieved over 50% reduction in schizophrenia symptoms intensity in comparison with patients taking medicines only
Trial summary: The clinical trial (RCT) aimed at assessing the efficacy of a 6-month intervention using a specific WKT n-3 composition (4 capsules BioCardine®Omega-3) as a supplementary therapy for the treatment using antipsychotics in patients with the first-episode schizophrenia. It is the world’s first such trial conducted in people.
It has especially been detected that in patients with first-episode schizophrenia the aforementioned nutritional intervention results in the reduction of schizophrenia symptoms described as: significant decrease in the disease symptoms measured with the PANSS scale and its subscale for general psychopathology, significant decrease in the intensity of depression symptoms measured with CDSS scale, significant improvement of the patient functioning measured with GAF scale, significant reduction of the disease symptoms intensity measured with CGI scale.
Together with significant increase in clinical parameters, the patients from treatment group showed an increasing cerebral cortex thickness in Brodmann areas 7 and 19 (by 2%), responsible for the development of schizophrenia symptoms. In patients from the placebo group using pharmacological treatment only the cerebral cortex thickness in these brain areas was reduced by more than 7%.
During the next experiments it was detected that WKT omega-3 supplementation reduces the oxidative damages by 123% in comparison with the placebo group and increases the efficacy of antioxidative protection (by 50%). It was also proven that the adopted nutritional intervention results in the increase in telomerase level, which is responsible for the reconstruction of telomeres (by 83% in the treatment group in comparison with the placebo group). It is believed that a decreased telomeres length and reduced telomerase activity may contribute to the development of schizophrenia.
Tomasz Pawełczyk, Marta Grancow-Grabka, Magdalena Kotlicka-Antczak, Elżbieta Trafalska, Agnieszka Pawełczyk. “A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia.” Journal of Psychiatric Research 73 (2016) 34-44
Deceleration of body aging processes by 19% as a result of the administration of NucleVital®Q10COMPLEX .
Infolge der dreimonatigen Einnahme von 6 Kapseln des Trial summary: During a 3-month clinical trial it was detected that daily administration of 6 NucleVital®Q10COMPLEX capsules significantly defers aging processes in women aged 35+. Among others, an increased activity of the so-called youth genes SIRT-1 by 15% and SIRT-2 by 17%, as well as an increase in the activity of enzymes preventing the decrease in telomeres length by 31% has been stated. It was also proven that thanks to the administration of NucleVital®Q10COMPLEX the human body increases the cell protection level against harmful impact caused by free radicals i.a. due to the increased activity of enzymes such as superoxide dismutase SOD by 19% and due to the increase in the antioxidative blood plasma capacity by 36%.
dr Aneta Balcerczyk, dr Agnieszka Gajewska, dr Ewa Macierzyńska-Piotrowska, dr n. med. Tomasz Pawełczyk, prof. dr hab. Grzegorz Bartosz, dr hab. prof. nadzw. Janusz Szemraj. Molecules 2014, 19(9), 14794-14808. Department of Molecular Biophysics, University of Lodz, Poland. Department of Affective and Psychotic Disorders, Medical University of Lodz,Poland. Department of Medical Biochemistry, Medical University in Lodz, Poland
Significant reduction of lipid parameters and the tendency aiming at the reduction of coronary incidents, including revascularization, in patients using medical nutrition BioMarine® and BioCardine®Omega-3.
Trial summary: This trial has proven that proper nutrition must not be forgotten even during medical therapies. The trial confirmed the efficacy of BioMarine® and BioCardine®Omega-3 with relation to human body protection.
Precautionary daily administration of 2 BioMarine®1140 capsules + 2 BioCardine®Omega-3 capsules in combination with standard treatment during 52 weeks in treatment group (MCS) of 31 persons resulted in a decrease in recurring coronary incidents and repeated revascularizations. And mostly important, in treatment group less events of death were recorded than in the control group.
Decrease in triglycerides level by 30% and decrease in LDL cholesterol level by 42% due to the administration of medical nutrition BioCardine®Omega-3 and red rice
Trial summary: With a daily administration of 3.8 g EPA + DHA Omega-3 (BioCardine®Omega-3 – 7 capsules) in combination with red rice extract for 12 weeks in patients with an increased cholesterol level (hypercholesterolemia), the total cholesterol level (TC) was reduced by 32%, the LDL-C fraction was reduced by 42% and triglycerides by 30%. The achieved results were much better than in patients from the control group administering 40 mg simvastatin.
The increase in antibacterial, antiviral and anticancer combat force as well as the immune system antigenicity.
The immune reaction of the body after the administration of BioMarine® is of a physiologically ordered nature, with a strength matching the hazards (healthy volunteers). Correctly built immune cells induce a profitable relationship between the production of cytokines IL-2/IL-10, meaning that the IL-2 increase is accompanied by IL-10 decrease. The increase in proinflammatory cytokine IL-2 secretion mobilises the immune system to the full readiness. This results in a significant activity increase of lymphocytes and macrophages, activity increase of neutrophils by 46% and activity increase of NK cells by 67%. This is manifested by a higher efficacy in the search for and destroying of pathogens. Lymphocytes that encounter danger points secrete interferon (IFN-γ) directly into the pathogen cells, thus preventing their multiplication.
Activated macrophages, neutrophils and NK cells increase the TNF-α production and cause a cascade reaction resulting in the elimination of pathogens and death of destroyed body cells. The regulation of cytokines extinguishing the excessive activity of the immune system (IL-10) is accompanied by the development of long-term immunity. Such a complex immune system reaction is characterised by high effectiveness with regard to the recognition, marking and destroying pathogens, without any side effects.
Very significant improvement of clinical parameters of psoriasis in 76% of patients
Trial summary: The works aimed at the evaluation of the impact of BioMarine®570 on the clinical development of psoriasis. Psoriasis is one of the most frequent skin diseases of chronic and recurring nature. The works proved that the human body possesses extreme regenerative properties, but only if it can be provided with proper structural substances. In this case it was squalene and alkylglycerols.
Daily administration of 3×4 BioMarine®570 capsules for 4 months resulted in an improvement of clinical parameters in 76% of patients. All the patients emphasised the improvement of general health condition, i.a. normalization of blood pressure and resolution of pruritus.
Immunity increase in healthy people by 40% to prevent the development of pathogens.
Trial summary: In order to successfully protect ourselves against the diseases we should also provide our body with proper nourishment when we are healthy. Using proper building and nourishing substances when we are in good health, we are able to strengthen our body even more against the attacks caused by bacteria, viruses and fungi.
Daily administration of 3×3 BioMarine®570 capsules for 1 month resulted in a statement that the preparation supports the natural immunity in healthy people. This may testify a possibly better response of the body in case of contact with pathogens. The body reacts much faster to the intrusion of pathogens and prevents the infection from spreading.
Reduction of inflammatory processes by 80% and serious health improvement in patients with rheumatoid arthritis
Trial summary: The authors examined the shark liver oil (BioMarine®570) for the natural immunity in people suffering from chronic rheumatoid arthritis (RA). The following natural immunity parameters were evaluated: complement system concentration, production of reactive oxygen species (ROS) and activity of NK cells.
Daily administration of 3×3 BioMarine®570 capsules for 3 months resulted in an increased cell activity as well as the activity of other immune system elements. The product significantly normalises the improvement of health condition in patients suffering from chronic rheumatoid arthritis. After the treatment with this product the parameters indicating the presence of RA showed a tendency towards the level present in healthy people.
Reduction of upper respiratory tract infections frequency by 20% as a result of administration of medical nutrition BioMarine®
Trial summary: These works were performed to evaluate the efficacy of compounds contained in shark liver oil with relation to the treatment of recurring upper respiratory tract infections based on the clinical assessment of patients and the impact of examined compounds on selected parameters of the inborn and acquired immunity.
Daily administration 3×3 BioMarine®570 capsules for 2 months resulted in a reduction of upper respiratory tract infections frequency by 20%. Stronger activation of cells responsible for our immunity increase has been obtained.
Reduction of bacterial and viral infections frequency in patients suffering from type 2 diabetes by 48%
Trial summary: The product BioMarine®570 applied in this trial has proven that proper building and nourishing substances are able to strengthen the human body even if its balance (health) has been upset. In patients suffering from type 2 diabetes squalene and alkylglycerols strengthened the immunity of their bodies.
Daily administration of 9 BioMarine®570 capsules for 1 month resulted in a reduced infections frequency in these patients from 67% till 19% in a year. Natural repair mechanisms in our body turn to be the most effective when it comes to fighting for our health.
Reduction of recurring aphtha frequency by 40% as a result of BioMarine®570 medical nutrition administration
Trial summary: The trial aimed at issuing a clinical assessment regarding the administration of an immunomodulating preparation, shark liver oil, in patients with recurring aphtha and its impact on the immune system. The trial constitutes an example, how our body can use the natural building substances to enhance the efficiency in a condition of an upset body balance.
Daily administration of 3×3 BioMarine®570 capsules for 3 months resulted in a reduction of recurring aphtha frequency by 40% during the first month after the trial and in an alleviation of the disease process.
Reduction of the upper respiratory tract infections frequency by 31% already after 2 months of nutritional intervention BioMarine®570.
Trial summary: 19 persons with recurring upper respiratory tract infections participated in the trial, with no systemic diseases and no other medication during the course of treatment. The product was applied in a dosage of 3 capsules 3 times a day for a period of two months. It was stated that the average number of recurrences and the upper respiratory tract infections frequency have been reduced in comparison with the condition before the treatment, on average from 1.32/month before the treatment till 0.91/month during the second month after the treatment. No negative side effects were observed during the administration of BioMarine®570.
Medical Study: 25, Number of patients: 355
Reduction of coronary incidents risk in patients undergoing cardiological treatment.
Summary: The administration of BioCardine®Omega-3 in an amount of 6 capsules daily within a period of 3 months in patients with diagnosed coronary artery disease undergoing statin therapy increases the efficacy of the applied therapy by approx. 20%. It has been observed that there is a reduced risk of new coronary incidents in patients with risk factors who applied fundamental building substances of the body (polyunsaturated fatty acid EPA and DHA Omega-3).
The impact of BioMarine® on immunity in the course of multiple sclerosis (MS).
Summary: The administration of BioMarine®570 in a patient with MS for one year resulted in a significant immunity improvement (no episodes of influenza, catarrh or urinary tract infections during this period). The patient felt more power and energy, the disease development has ceased (dosage: 12 capsules a day).
The administration of BioMarine® in children with allergies.
Summary: The administration of BioMarine®570 in small children caused a reduction of allergic skin reactions only after 14 days of administration, a milder course of allergic rhinitis, especially the resolution of nose blockade after 30 days of treatment. Positive effects in the treatment of rickets were also observed, in correlation with BioMarine®570 and vitamin D3. The dosage of BioMarine®570 was established individually based on the patient’s condition, the nature of the disease and body weight.
Infection duration reduced by 50% and immediate recovery.
Summary of 2 trials: 40 patients with severe viral upper respiratory tract infections participated in two parallel medical trials (20 patients in the treatment group and 20 patients in the control group) and applied daily 14 BioMarine®1140 capsules + 10 BioCardine®Omega-3 capsules + 6 NucleVital®Q10complex capsules for 14 days. After 7 days already the administration of the aforementioned preparations resulted in a significantly better wellbeing, resolution of disease symptoms (normalised temperature, less cough, catarrh and resolution of muscle pain) and no recurring viral infections within a period of 4-6 weeks.
Shorter infertility treatment time, reduced miscarriage risk and premature birth risk, complete lack of postpartum depression symptoms and normalisation of birth weight as well as the lack of neurological disorders in infants.
Trial summary: Daily administration of 2-4 BioMarine®1140 capsules for a period of 9 months in women undergoing infertility treatment due to reproductive tract infections led to significantly faster resolution of the inflammation and a shorter infertility treatment period.
Daily administration of 2-4 BioCardine®Omega-3 capsules in women during preconception care as well as during the whole pregnancy resulted in a reduced miscarriage risk and premature birth risk, normalisation of the baby’s birth weight and complete lack of postpartum depression symptoms as well as the lack of neurological disorders in infants.
Significant reduction of the frequency of respiratory system infections and serious alleviation of asthma bronchiale symptoms in children. Visible blood pressure regulation, increasing medical treatment efficacy and reduced insulin resistance in patients with cardiological disorders.
Trial summary: Daily administration of 2 BioMarine®570 capsules for 8 months in healthy children aged 3-17 and in children with asthma bronchiale as well as with recurring upper respiratory tract infections resulted in a reduced upper respiratory tract infections frequency and a milder infection process, furthermore the alleviation of asthma bronchiale symptoms.
Daily administration of 2 BioCardine®Omega-3 capsules for 8 months in patients suffering from cardiological disorders resulted in blood pressure improvement, increased physical performance, reduced amounts of medicines taken, reduced insulin resistance.
Reduction of infection frequency during winter and spring time in children with decreased immunity by 50% on average.
Trial summary: Daily administration of BioMarine®570 in a dose of 10 mg alkylglycerols / kg body weight for 4 months in children aged 6-18 with recurring upper respiratory tract infections, bronchitis and asthma bronchiale resulted in a reduced number of incidents in the respective period and strengthening the immune system of the body, visible as better results of morphological tests.
Significantly reduced number of incidents, better appetite and substantial hair condition improvement in children.
Trial summary: Daily administration of 2 BioMarine®570 capsules for 4 months in children with increased susceptibility to upper respiratory tract infections, metabolic disorders and recurring hair loss resulted in a reduced number of incidents, better appetite and stronger hair.
55% of children with significant reduction of recurring infections frequency and 40% of children with milder course of infections.
Trial summary: Daily administration of 1-2 BioMarine®570 capsules for 5 months in children aged 1-7 with recurring upper respiratory tract infections, rhinitis and atopic dermatitis (AD) resulted in a reduced frequency of recurring symptoms (55% of patients) and a milder course of infections (40% of patients).
Visible improvement of dermatologic skin condition and significant alleviation of allergic symptoms in the course of atopic dermatitis.
Trial summary: Daily administration of 4 BioMarine®570 capsules and 2 BioCardine® capsules and of the preparation La®Squalana on skin for 8 months in patients with skin disorders: acne, psoriasis and atopic dermatitis (AD) resulted in a significant improvement of the dermatologic skin condition and alleviation of allergy symptoms in case of AD. The positive changes allowed the patients to reduce the number of the applied steroidal cremes and ointments.
Reduced triglycerides concentration by 7% on average, significant improvement of physical performance and visible reduction of heart palpitations, confirmed by ECG.
Trial summary: Daily administration of 6 BioCardine® capsules for 4 months in patients with a stable coronary artery disease and high triglycerides level resulted in an improved physical performance, reduced heart palpitations confirmed by ECG and reduced triglycerides level by 6% on average.
Reduced total cholesterol level, LDL cholesterol and triglycerides level as well as increased HDL cholesterol level in patients with cardiological disorders.
Trial summary: Daily administration of 2 BioCardine® capsules for 6 months as a standard treatment supplement in patients with stable coronary artery disease and mixed hyperlipidaemia resulted in additional decrease in total cholesterol level by 13.3%, LDL cholesterol level by 15.8%, triglycerides level by 12.5% and an increase in HDL cholesterol level by 30%. An additional increase in strain tolerance by 13.3% has also been stated.
Significantly lower frequency of further coronary angiography procedures and of recurring coronary disorders.
Trial summary: Daily administration of 2 BioCardine® capsules for 2.5 months as a standard treatment supplement in hospitalised patients undergoing a coronary angioplasty treatment resulted in a reduction of recurring coronary disorders and reduced frequency of further coronary angiography procedures.
Physiological regulation of the lipid profile and blood pressure in patients with stable coronary artery disease.
Trial summary: Daily administration of 3 BioCardine® capsules for 6 months as a standard treatment supplement in patients with stable coronary artery disease and idiopathic hypertension resulted in a decrease in total cholesterol level by 5%, LDL cholesterol level by 11%, triglycerides level by 12% and in a lower blood pressure: systolic blood pressure by 5.5% and diastolic blood pressure by 4%.
Decrease in total cholesterol level and triglycerides level in patients with coronary artery disease. Significant physical condition improvement.
Trial summary: Daily administration of 2 BioCardine® capsules + 2 BioMarine®1140 capsules for 6 months as standard treatment supplement in patients with stable coronary artery disease resulted in a decrease in total cholesterol level by 7.6% and triglycerides level by 9.8%. Additionally, a physical condition improvement and skin condition improvement were observed.
Increased medical treatment efficacy by strengthening the immune system in a patient suffering from fungal infection of the upper respiratory tract.
Trial summary: In a patient suffering from chronic pulmonary aspergillosis treated for over 4 years using different kinds of antibiotics without success, the additional daily administration of 6 BioMarine®1140 capsules for a period of 12 months resulted in a significant improvement of health condition and strengthening vital forces as well as the immune system of the body.
Reduced frequency of complications after the infections by 20% and shorter duration of infections.
Trial summary: Daily administration of 6 BioMarine®1140 capsules for 7 days and subsequently the daily administration of 4 capsules for 4 months in patients with recurring nasopharyngitis and bronchitis resulted in a milder and shorter course of infections and a reduction of complications frequency after the infections by 20%.
Reduction of triglycerides level and regulation of other parameters in patients with cardiological disorders. Strengthening the immune system in patients with recurring infections.
Trial summary: Daily administration of 2 BioMarine®1140 capsules for 3 months (including preliminary correction dose of 15 capsules for 7 days) in patients with recurring upper respiratory tract infections: nasopharyngitis, laryngitis and tracheitis, decreased immunity and asthma bronchiale resulted in a stronger immune system and reduced severity in the course of infections, with no need to introduce antibiotic therapy.
Daily administration of 2-6 BioCardine® capsules for 3 months in patients with coronary artery disease, hypertension and thrombosis, as well as lipid disorders, resulted in a decrease in triglycerides level by up to 40% and in a decrease in total cholesterol level and LDL fraction, as well as in an increase in HDL fraction.
Reduced duration of infections and restoring the proper total cholesterol level in 90% of patients.
Trial summary: Daily administration of 2-3 BioMarine®1140 capsules for 3 months in patients with inborn decreased immunity and recurring viral upper respiratory tract infections resulted in strengthening the immune system and reduced frequency of infections.
Daily administration of 2-4 BioCardine® capsules for 3-4 months in patients with increased cholesterol level >250 mg/dl and triglycerides level >200 mg/dl resulted in a decrease in total cholesterol level under 200 mg/dl and decrease in triglycerides level by 50% on average in 90% of patients.
Improved function of the respiratory system, better wellbeing and physical performance as well as proper regulation of lipid parameters in blood in patients with reduced immunity and in patients with cardiological disorders.
Trial summary: Daily administration of 2 BioMarine®1140 capsules for 3 months in patients with lower immunity resulted in a reduction of respiratory tract conditions (60% of patients), reduced musculoskeletal system conditions (40% of patients), improved physical condition (80% of patients) and in a generally stronger body (40% of patients).
Daily administration of 2-3 BioCardine® capsules for 3 months in patients with cardiological disorders resulted in a better wellbeing and physical performance (60% of patients), reduced total cholesterol level (35% of patients) and balanced blood pressure (15% of patients).
Noticeably improved function of the gastrointestinal tract and significantly reduced brittleness of hair and loss of hair. Regulation of the lipid profile reaching the correct values together with the improvement of the general heart performance and vascular performance.
Trial summary: Daily administration of 2 BioMarine®1140 capsules for 6 months in a patient susceptible to hair loss and to the gastrointestinal tract disorders (constipation) resulted in an improved function of the gastrointestinal tract and reduced brittleness in hair and hair loss.
Daily administration of 4 BioCardine® capsules + 2 BioMarine®1140 capsules for 4 months in a patient with high LDL cholesterol level and statin intolerance resulted in a decrease in total cholesterol level by 60 mg/dl and for LDL fraction by approx. 45 mg/dl together with an improvement of heart performance and vascular performance.
Reduced frequency of incidents, increase in vital forces, visible remission of skin lesions. Reduced triglycerides level and alleviation of unpleasant menopause conditions.
Trial summary: Daily administration of 4 BioMarine®570 capsules for 3 months in patients with frequent upper respiratory tract infections and general debility, as well as in patients with atopic dermatitis and psoriasis resulted in a reduced frequency of incidents and increase in vital forces (90% of patients), shorter infection duration (10% of patients) as well as in remission of skin lesions.
Daily administration of 3 BioCardine® capsules for 3 months in patients with coronary artery disease and cardiac arrhythmia resulted in a decrease in triglycerides level by approx. 40% and in a reduction of LDL cholesterol level. Additionally, in women after menopause an alleviation of unpleasant menopause conditions has been stated.
Visible reduction of severity of skin lesions caused by acne, psoriasis and atopic dermatitis. Regulation of the lipid profile, improved physical performance and alleviation of side effects of medicines.
Trial summary: Daily administration of 4 BioMarine®570 capsules for 8 months in patients with skin problems resulted in a significantly lower severity of such lesions as acne, psoriasis and atopic dermatitis, as well as improved immunity and shorter duration of the lower and upper respiratory tract infections.
Daily administration of 2 BioCardine® capsules for 8 months in patients with cardiological disorders resulted in a lower cholesterol and triglycerides concentration, better physical performance and resolution of conditions related to the administration of other medicines.
Physical performance improvement and strengthening the body. Reduced frequency of infections and significantly shorter duration of infections, as well as complete resolution of recurring aphtha.
Trial summary: Daily administration of 4 BioMarine®570 capsules for 7 months in patients with recurring lower and upper respiratory tract infections and recurring aphtha resulted in a significantly lower infections frequency and reduced severity in the course of infections, as well as complete resolution of recurring aphtha.
Daily administration of 2 BioCardine® capsules for 7 months in patients with coronary artery disease and hypertension resulted in a better physical performance and general improvement of the body condition in 90% of patients.
Reduced frequency of infections and reduced severity in the course of infections, with no need to introduce antibiotic therapy. Reduced triglycerides level and better physical performance.
Trial summary: Daily administration of 3-5 BioMarine®570 capsules for 3 months in patients with recurring upper respiratory tract infections: nasopharyngitis, laryngitis and tracheitis resulted in a lower infections frequency and reduced severity in the course of infections, with no need to introduce antibiotic therapy in 60% of patients.
Daily administration of 2 BioCardine® capsules for 3 months in patients with coronary artery disease, hypertension and hyperlipidaemia resulted in a decrease in triglycerides level by approx. 8% and in a better physical performance of the body.
